WO2011036297A3 - Méthode de thérapie et de diagnostic de morbus alzheimer - Google Patents

Méthode de thérapie et de diagnostic de morbus alzheimer Download PDF

Info

Publication number
WO2011036297A3
WO2011036297A3 PCT/EP2010/064289 EP2010064289W WO2011036297A3 WO 2011036297 A3 WO2011036297 A3 WO 2011036297A3 EP 2010064289 W EP2010064289 W EP 2010064289W WO 2011036297 A3 WO2011036297 A3 WO 2011036297A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
diagnosis
therapy
disease
membrane
Prior art date
Application number
PCT/EP2010/064289
Other languages
German (de)
English (en)
Other versions
WO2011036297A2 (fr
Inventor
Helmut E. Meyer
Original Assignee
Ruhr-Universität-Bochum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruhr-Universität-Bochum filed Critical Ruhr-Universität-Bochum
Priority to EP10757220A priority Critical patent/EP2504024A2/fr
Publication of WO2011036297A2 publication Critical patent/WO2011036297A2/fr
Publication of WO2011036297A3 publication Critical patent/WO2011036297A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode de thérapie et de diagnostic de Morbus Alzheimer ayant pour objet des récepteurs tyrosine-kinases et/ou des récepteurs membranaires à cytokines y compris des anticorps auto-immuns impliqués.
PCT/EP2010/064289 2009-09-27 2010-09-27 Méthode de thérapie et de diagnostic de morbus alzheimer WO2011036297A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10757220A EP2504024A2 (fr) 2009-09-27 2010-09-27 Méthode de thérapie et de diagnostic de morbus alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171429.5 2009-09-27
EP09171429 2009-09-27

Publications (2)

Publication Number Publication Date
WO2011036297A2 WO2011036297A2 (fr) 2011-03-31
WO2011036297A3 true WO2011036297A3 (fr) 2011-10-20

Family

ID=43447835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/064289 WO2011036297A2 (fr) 2009-09-27 2010-09-27 Méthode de thérapie et de diagnostic de morbus alzheimer

Country Status (2)

Country Link
EP (1) EP2504024A2 (fr)
WO (1) WO2011036297A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2989158B1 (fr) 2012-04-04 2014-04-18 Commissariat Energie Atomique Procede de realisation d'un module d'echangeur de chaleur a au moins deux circuits de circulation de fluide.
WO2015152413A1 (fr) * 2014-04-03 2015-10-08 地方独立行政法人東京都健康長寿医療センター Biomarqueur pour diagnostic de vieillissement ou d'amyotrophie
WO2017050976A1 (fr) * 2015-09-23 2017-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides ephb2 et leurs utilisations pour le diagnostic et le traitement du lupus
CN116626294B (zh) * 2022-09-20 2024-07-09 菲创生物医学技术(广州)有限公司 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030326A1 (fr) * 1994-04-29 1995-11-09 Mount Sinai Hospital Corporation Tyrosine-kinase receptrice neuronale
WO1997021811A2 (fr) * 1995-12-15 1997-06-19 Regeneron Pharmaceuticals, Inc. Nouveaux recepteurs du type tyrosine kinase et ligands
US5656473A (en) * 1993-07-21 1997-08-12 Regeneron Pharmaceuticals, Inc. Human Dmk receptor
WO1998045708A1 (fr) * 1997-04-08 1998-10-15 Sugen, Inc. Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
WO1999064589A1 (fr) * 1998-06-11 1999-12-16 Astrazeneca Ab Recepteur humain tyrosine kinase
WO2004063362A2 (fr) * 2003-01-10 2004-07-29 Cyclacel Limited Proteines de la progression du cycle cellulaire
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20070128633A1 (en) * 2005-10-11 2007-06-07 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009092049A1 (fr) * 2008-01-17 2009-07-23 Irm Llc Anticorps anti-trkb améliorés
WO2009100859A1 (fr) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Prédiction de toxicité de la moelle osseuse

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346413B1 (en) 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656473A (en) * 1993-07-21 1997-08-12 Regeneron Pharmaceuticals, Inc. Human Dmk receptor
WO1995030326A1 (fr) * 1994-04-29 1995-11-09 Mount Sinai Hospital Corporation Tyrosine-kinase receptrice neuronale
WO1997021811A2 (fr) * 1995-12-15 1997-06-19 Regeneron Pharmaceuticals, Inc. Nouveaux recepteurs du type tyrosine kinase et ligands
WO1998045708A1 (fr) * 1997-04-08 1998-10-15 Sugen, Inc. Etude et traitement des maladies liees a des fonctions cellulaires specifiques de proteines tyrosines kinases receptrices
WO1999064589A1 (fr) * 1998-06-11 1999-12-16 Astrazeneca Ab Recepteur humain tyrosine kinase
WO2004063362A2 (fr) * 2003-01-10 2004-07-29 Cyclacel Limited Proteines de la progression du cycle cellulaire
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20070128633A1 (en) * 2005-10-11 2007-06-07 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009092049A1 (fr) * 2008-01-17 2009-07-23 Irm Llc Anticorps anti-trkb améliorés
WO2009100859A1 (fr) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Prédiction de toxicité de la moelle osseuse

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOPEZ O L ET AL: "SERUM AUTOANTIBODIES IN PATIENTS WITH ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA AND IN NONDEMENTED CONTROL SUBJECTS", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 23, no. 8, 1 January 1992 (1992-01-01), pages 1078 - 1083, XP009085324, ISSN: 0039-2499 *
PERDIVARA IRINA ET AL: "Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry", GLYCOBIOLOGY, vol. 19, no. 9, September 2009 (2009-09-01), pages 958 - 970, XP002621663, ISSN: 0959-6658 *

Also Published As

Publication number Publication date
WO2011036297A2 (fr) 2011-03-31
EP2504024A2 (fr) 2012-10-03

Similar Documents

Publication Publication Date Title
SMT201700102B (it) Anticorpi umani di alta affinitá al recettore attivato dalle proteasi-2 umano
HUS1800047I1 (hu) Humán CGRP receptor kötõ ellenanyagok
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
MY155621A (en) Axl antibodies
WO2010004204A3 (fr) Antagonistes specifiques du recepteur fgf-r4
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
AP2012006343A0 (en) Neutralizing prolactin receptor antibodies and their therapeutic use.
WO2010128407A3 (fr) Anticorps anti-il-17f et leurs méthodes d'utilisation
WO2011044311A3 (fr) Génération, caractérisation et utilisations d'anticorps anti-her3
EP2358371A4 (fr) Antagonistes du récepteur p2x3 pour le traitement de la douleur
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
WO2010081679A3 (fr) Anticorps dirigés contre le récepteur humain de l'érythropoïétine
MX358367B (es) Anticuerpos para el receptor de la barrera hematoencefálica de baja afinidad y sus usos.
MX2011011825A (es) Anticuerpos humanizados para axl.
WO2009021293A8 (fr) Agents et procédés de modulation d'une activité de cytokine inhibitrice des macrophages (mic-1)
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PT1729753E (pt) Utilização de um antagonista dos receptores de nmda para o tratamento de zumbido induzido por excitotoxicidade coclear
WO2007114861A3 (fr) Antagonistes du recepteur de il-21
TN2011000463A1 (en) Composition and methods for increasing muscle growth
WO2011080209A3 (fr) Nouvelle formation d'anticorps
EP1781818A4 (fr) Procedes de diagnostic utilisant des anticorps anti-recepteur de cytokine
EP2826791A3 (fr) Anticorps anti-C5aR humanisés
WO2013188448A3 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
WO2012103360A3 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
WO2010070658A3 (fr) Procédé amélioré de synthèse d'antagonistes de récepteur de l'endothéline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10757220

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010757220

Country of ref document: EP